MedTrace Logo

MP-AzeFlu Allergen Chamber - Onset of Action Study

NCT03004131 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2022-02-22

No results posted yet for this study

Summary

This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Chamber (EEC).

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

Azelastine hydrochloride + fluticasone propionate nasal spray

DRUG

Placebos

DRUG

fluticasone propionate nasal spray + loratadine

Sponsors & Collaborators

  • MEDA Pharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Christine Kolb · MEDA Pharma GmbH & Co. KG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-07
Primary Completion
2017-03-29
Completion
2017-03-29

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004131 on ClinicalTrials.gov